Author Correction to ‘mevalonate Improves Anti-Pd-1/pd-l1 Efficacy by Stabilizing CD274 Mrna’ [acta Pharmaceutica Sinica B 13 (2023) 2585–2600]

Wenxin Zhang,Xiaohui Pan,Yanjun Xu,Hongjie Guo,Mingming Zheng,Xi Chen,Honghai Wu,Fengming Luan,Qiaojun He,Ling Ding,Bo Yang

DOI: https://doi.org/10.1016/j.apsb.2023.07.023

IF: 14.903

2023-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2023.04.002.].

What problem does this paper attempt to address?

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Wenxing Chen,Yanhong Pan,Siliang Wang,Yuping Liu,Guangying Chen,Liang Zhou,Chao Zhang,Wenting Ni,Aiyun Wang,Yin Lu,Shile Huang

DOI: https://doi.org/10.1186/s12885-019-5458-y

IF: 4.638

2019-01-01

BMC Cancer

Abstract:Following publication of the original article [1], the author noticed the following errors in the article.
Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Xiang P. Liu,Li J. Gao,Ben T. She,Gui X. Li,Yun R. Wu,Ji M. Xu,Zhong J. Ding,Jian F. Ma,Shao J. Zheng

DOI: https://doi.org/10.1111/pce.14419

2022-01-01

Abstract:In the published article, the author names in the byline which originally appeared as “Xiang P. Liu, Li J. Gao, Ben T. She, Gui X. Li, Yun R. Wu, Ji M. Xu, Zhong J. Ding, Jian F. Ma, Shao J. Zheng” have been corrected to “Xiangpei Liu, Lijun Gao, Bentao She, Guixin Li, Yunrong Wu, Jiming Xu, Zhongjie Ding, Jianfeng Ma, Shaojian Zheng” in the byline and the ORCID ID section. We apologize for this error.
Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Xia Li,Xiufeng Yin,Huafeng Wang,Jiansong Huang,Mengxia Yu,Zhixin Ma,Chenying Li,Yile Zhou,Xiao Yan,ShuJuan Huang,Jie Jin

DOI: https://doi.org/10.18632/oncotarget.27310

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.14463.].
Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Zhilin Li,Hao Cai,Zhiqian Li,Long Ren,Xuelei Ma,Hongyan Zhu,Qiyong Gong,Hu Zhang,Zhongwei Gu,Kui Luo

DOI: https://doi.org/10.1016/j.bioactmat.2022.09.016

IF: 18.9

2023-04-01

Bioactive Materials

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2022.08.028.].

engineering, biomedical,materials science, biomaterials
Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes & Diseases 9(2022) 443–455]

Xiaohua Shen,Chunhua Weng,Yucheng Wang,Cuili Wang,Feng Shi,Xiayu Li,Heng Li,Hong Jiang,Haibing Wang,Jianghua Chen

DOI: https://doi.org/10.1016/j.gendis.2022.03.001

IF: 7.376

2022-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2020.07.005.][This corrects the article DOI: 10.1016/j.gendis.2021.09.001.].
Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Han Yao,Jiang Lan,Chushu Li,Hubing Shi,Jean-Philippe Brosseau,Huanbin Wang,Haojie Lu,Caiyun Fang,Yao Zhang,Lunxi Liang,Xiaolin Zhou,Chaojun Wang,Yu Xue,Yun Cui,Jie Xu

DOI: https://doi.org/10.1038/s41551-019-0402-7

IF: 28.1

2019-04-11

Nature Biomedical Engineering

Abstract:In the version of this Article originally published, ‘palmitoyltransferase ZDHHC3 (DHHC3)’ was incorrectly referred to as an ‘acetyltransferase’ rather than an as an ‘acyltransferase’; this has now been corrected in five instances. In Fig. 3a, the label for the bottom row of the blots was mistakenly written as ‘GAPHD’; it should have read ‘GAPDH’. In the two right-most panels of Fig. 4j, the antibody labels ‘α-PD-L1’ for the reciprocal co-immunoprecipitation of DHHC3 were incorrect; they should have been ‘α-DHHC3’. These errors have been corrected in all versions of the Article.

engineering, biomedical
Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

W-H Zhang,S-M Zhao,J-F Guo,Y-P Liu,Y-Q Jiang

DOI: https://doi.org/10.26355/eurrev_202307_32944

2023-01-01

European review for medical and pharmacological sciences

Abstract:Correction to: Eur Rev Med Pharmacol Sci 2023; 27 (9): 4098-4102. DOI: 10.26355/eurrev_202305_32317-PMID: 37203835-published online on May 15, 2023. After publication, the authors applied a correction in the Funding section. The section has been amended as follows: This study was supported by the research program of Jilin Provincial Science and Technology Department (No. 20190201011J). There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/32317.
Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Pengzhao Shang,Rui Gao,Yijia Zhu,Xiaorui Zhang,Yang Wang,Minji Guo,Hui Peng,Min Wang,Juan Zhang

DOI: https://doi.org/10.1016/j.apsb.2024.02.014

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2020.09.008.].
Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:
Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Yi Qian,Meimei Zhao,Qinghua Han,Jingkang Wang,Lixi Liao,Heng Yang,Dan Liu,Pengfei Tu,Hong Liang,Kewu Zeng

DOI: https://doi.org/10.1016/j.apsb.2024.02.013

IF: 14.903

2024-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2021.01.011.].
Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Wei Wang,Bo Hu,Jiang-Jiang Qin,Jianwen Cheng,Xin Li,Mehrdad Rajaei,Jia Fan,Xin-Rong Yang,Ruiwen Zhang

DOI: https://doi.org/10.1016/j.gendis.2019.12.006

IF: 7.376

2019-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2019.06.001.].
Author correction to ‘Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy’ [Acta Pharmaceutica Sinica B 11 (2021) 3508–3526]

Shuyi Wang,Jun Tao,Huaguo Chen,Machender R. Kandadi,Mingming Sun,Haixia Xu,Gary D. Lopaschuk,Yan Lu,Junmeng Zheng,Hu Peng,Jun Ren

DOI: https://doi.org/10.1016/j.apsb.2022.12.015

IF: 14.903

2023-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2021.07.006.].
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524

Dongxiao Fan,Chenshu Liu,Zhongyu Zhang,Kan Huang,Tengyao Wang,Sifan Chen,Zilun Li

DOI: https://doi.org/10.3390/molecules29204840

IF: 4.6

2024-10-13

Molecules

Abstract:Molecules, Vol. 29, Pages 4840: Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524 Molecules doi: 10.3390/molecules29204840 Authors: Dongxiao Fan Chenshu Liu Zhongyu Zhang Kan Huang Tengyao Wang Sifan Chen Zilun Li Text Correction [...]

chemistry, multidisciplinary,biochemistry & molecular biology
Corrigendum to “ethyl Pyruvate Ameliorates Hepatic Ischemia-Reperfusion Injury by Inhibiting Intrinsic Pathway of Apoptosis and Autophagy”

Song Miao,Jie Lü,Weiqi Dai,Wei Fan,Ling Xu,Kan Chen,Lei He,Ping Cheng,Yan Zhang,Chengfen Wang,Dong Wu,Jing Yang,Rong Zhu,Huawei Zhang,Yingqun Zhou,Chuanyong Guo

DOI: https://doi.org/10.1155/2016/5434275

2016-01-01

Mediators of Inflammation

Abstract:[This corrects the article DOI: 10.1155/2013/461536.].
Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Zekun Li,Yongchun Pan,Shiyu Du,Yayao Li,Chao Chen,Hongxiu Song,Yueyao Wu,Xiaowei Luan,Qin Xu,Xiaoxiang Guan,Yujun Song,Xin Han

DOI: https://doi.org/10.1016/j.apsb.2023.09.002

IF: 14.903

2023-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2022.06.016.].
Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Zekun Li,Yongchun Pan,Shizheng Du,Yayao Li,Chao Chen,Hongxiu Song,Yueyao Wu,Xiaowei Luan,Qiang Xu,Xiaoxiang Guan,Yujun Song,Xin Han

DOI: https://doi.org/10.1016/j.apsb.2023.09.002

IF: 14.903

2024-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2022.06.016.].
Corrigendum to"Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment" [Bioact Mater 24 (2022) 37-53]

Haotian Shen,Lulu Jin,Qiangqiang Zheng,Ziqiang Ye,Linxiang Cheng,Yuxu Wu,Honghao Wu,Tae Gyong Jon,Wenduo Liu,Zongyou Pan,Zhengwei Mao,Yue Wang

DOI: https://doi.org/10.1016/j.bioactmat.2024.08.007

2024-08-22

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2022.12.001.].
Corrigendum: A Novel Role of Connexin 40-Formed Channels in the Enhanced Efficacy of Photodynamic Therapy

Deng-Pan Wu,Li-Ru Bai,Yan-Fang Lv,Yan Zhou,Chun-Hui Ding,Si-Man Yang,Fan Zhang,Yuan-Yuan Wang,Jin-Lan Huang,Xiao-Xing Yin

DOI: https://doi.org/10.3389/fonc.2022.853278

IF: 4.7

2022-02-23

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2019.00595.].

oncology
Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]

Wan-Xin Peng,Fei Liu,Jia-Hong Jiang,Hang Yuan,Ziqiang Zhang,Liu Yang,Yin-Yuan Mo

DOI: https://doi.org/10.1016/j.gendis.2024.101352

2024-06-15

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2022.02.014.].

Author Correction to ‘mevalonate Improves Anti-Pd-1/pd-l1 Efficacy by Stabilizing CD274 Mrna’ [acta Pharmaceutica Sinica B 13 (2023) 2585–2600]

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes &amp; Diseases 9(2022) 443–455]

Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Author correction to ‘Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy’ [Acta Pharmaceutica Sinica B 11 (2021) 3508–3526]

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524

Corrigendum to “ethyl Pyruvate Ameliorates Hepatic Ischemia-Reperfusion Injury by Inhibiting Intrinsic Pathway of Apoptosis and Autophagy”

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Corrigendum to"Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment" [Bioact Mater 24 (2022) 37-53]

Corrigendum: A Novel Role of Connexin 40-Formed Channels in the Enhanced Efficacy of Photodynamic Therapy

Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]

Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes & Diseases 9(2022) 443–455]